In:
Nephron, S. Karger AG, Vol. 140, No. 3 ( 2018), p. 161-168
Kurzfassung:
〈 b 〉 〈 i 〉 Objective: 〈 /i 〉 〈 /b 〉 This study investigated the effects of sucroferric oxyhydroxide on fibroblast growth factor (FGF)-23 and dose reduction of erythropoiesis-stimulating agents (ESA) and intravenous saccharated ferric oxide in hemodialysis patients. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 In this prospective, open-label, parallel-group, multicenter trial involving patients receiving lanthanum carbonate hydrate, eligible patients were randomized to a sucroferric oxyhydroxide group or a control group. Hemoglobin, serum phosphate, FGF-23, iron, and ferritin levels, as well as transferrin saturation, doses of intravenous saccharated ferric oxide and ESA administered, and the erythropoietin responsiveness index (ERI) were monitored for 24 weeks. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Sixty-eight eligible patients were allocated to receive sucroferric oxyhydroxide ( 〈 i 〉 n 〈 /i 〉 = 34) or serve as controls ( 〈 i 〉 n 〈 /i 〉 = 34). Data for 31 patients in the sucroferric oxyhydroxide group and 32 in the control group were analyzed. Serum phosphate was equally well controlled in both groups. In the sucroferric oxyhydroxide group, intact FGF-23 levels decreased significantly from baseline at the end of the study ( 〈 i 〉 p 〈 /i 〉 = 0.01) and there was a significant difference compared with the control group ( 〈 i 〉 p 〈 /i 〉 = 0.035). Required doses of ESA and ERI were significantly reduced in the sucroferric oxyhydroxide group decreased significantly. The dose of intravenous saccharated ferric oxide required in the sucroferric oxyhydroxide group was significantly lower than that at baseline ( 〈 i 〉 p 〈 /i 〉 = 0.006) and in the control group ( 〈 i 〉 p 〈 /i 〉 = 0.003). 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Treatment of hyperphosphatemia with sucroferric oxyhydroxide was effective in patients on hemodialysis, resulting in decreased serum FGF-23 levels and a reduction in the required dose of saccharated ferric oxide.
Materialart:
Online-Ressource
ISSN:
1660-8151
,
2235-3186
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2018
ZDB Id:
2810853-X
